charts 8/2013 and 1/2014
Jan 2014
August 2013
Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs in Australia. The company offers PBT-2, a Phase IIa clinical trial product for the treatment of Alzheimer's disease. Its product is designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company's product is also applied for other therapies, including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinson's disease, and other neurodegenerative diseases. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.
Key stats and ratios
|
| Net profit margin | -148.03% | -167.85% |
| Operating margin | -148.03% | -167.85% |
| EBITD margin | - | -170.01% |
| Return on average assets | -46.12% | -63.79% |
| Return on average equity | -58.80% | -79.47% |
| Employees | 9 |
Address
Level 2, 369 Royal Parade, Parkville
Parkville, VIC 3052
Australia
No comments:
Post a Comment